Expression of Herpes Virus Entry Mediator (HVEM) in the Cornea and Trigeminal Ganglia of Normal and HSV-1 Infected Mice

2009 ◽  
Vol 34 (10) ◽  
pp. 896-904 ◽  
Author(s):  
S. Krisztian Kovacs ◽  
Vaibhav Tiwari ◽  
Emese Prandovszky ◽  
Sandor Dosa ◽  
Sarolta Bacsa ◽  
...  
2016 ◽  
Vol 2 (1) ◽  
pp. 14-15

Ziele: Beurteilung der Rolle des «herpes virus entry mediator» (HVEM) beim Viruseintritt und der Produktion inflammatorischer Zytokine in Reaktion auf eine Stimulation mit dem Herpes-simplex-Virus Typ 1 (HSV-1) in humanen Hornhaut-Epithelzellen. Methoden: Die HVEM-Expression in humanen Hornhaut-Epithelzellen wurde mittels Immunfluoreszenz und Durchflusszytometrie bestimmt. Mit β-Galaktosidase-exprimierendem HSV-1 wurden die Hornhaut-Epithelzellen stimuliert, und Viruseintrittstests wurden durchgeführt, um den Eintritt von HSV-1 in die Zellen zu überprüfen. Die Konzentrationen der Zytokine TNF-α, IL-6, IFN-γ, IL-12 und IL-18 sowie der Chemokine MIP-1α, MIP-1β und MIP-2 in Reaktion auf die HSV-1-Stimulation wurden in mit Kontrollsubstanz oder HVEM-siRNA behandelten Hornhaut-Epithelzellen untersucht. Ergebnisse: Die humanen Hornhaut-Epithelzellen waren positiv für HVEM-Expression und zeigten eine hohe Suszeptibilität für den Eintritt von HSV-1. Ein HVEM-«Silencing» bewirkte keine wesentliche Veränderung des Viruseintritts. Allerdings wurden nach der HSV-1-Stimulation in den mit HVEM-siRNA behandelten Zellen im Vergleich zu den Kontrollzellen höhere Konzentrationen des Zytokins IFN-γ sowie der Chemokine MIP-1α und MIP-1β gemessen. Schlussfolgerungen: HVEM in menschlichen Hornhaut-Epithelzellen kann die Produktion bestimmter Zytokine und Chemokine dämpfen und dadurch die angeborene Immunreaktion gegen HSV-1 modulieren. Dies könnte ein bisher unbekannter Mechanismus in der Pathogenese der HSV-1-Infektion der Hornhaut sein. Übersetzung aus Ophthalmic Res 2015;54:128-134 (DOI: 10.1159/000437209)


2014 ◽  
Vol 16 (8) ◽  
pp. 648-660 ◽  
Author(s):  
Shalini Sharma ◽  
Naveen K. Rajasagi ◽  
Tamara Veiga-Parga ◽  
Barry T. Rouse

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi256-vi256
Author(s):  
Ming-Zhi Han ◽  
Shuai Wang ◽  
Dong-Hai Wang

Abstract BACKGROUND Dysregulation of immune checkpoint members within tumors, including glioblastoma (GBM), is related to immune evasion. Herpes virus entry mediator (HVEM) is a novel identified immune checkpoint molecule which plays essential roles in both innate and acquired immunity. Despite recent advances in exploring the function HVEM in a variety cancer types, the clinical and immunological importance of HVEM in human gliomas remain largely unknown. METHODS Molecular and clinical data was obtained from publicly genomic databases. Immunohistochemistry was applied to assess the protein level of HVEM. Matlab software as well as R language were used for statistical analysis. RESULTS HVEM was found to be elevated in aggressive gliomas, especially in isocitrate dehydrogenase (IDH) wild-type GBM. High expression of HVEM was associated with Mesenchymal subtype and showed promising prognostic values based on Cox regression model and nomogram model. HVEM showed intra-tumor heterogeneity with abundant in peri-necrotic zone and microvascular region. In addition, HVEM high patients were more frequent with genomic aberrations of oncogenic events. Gene ontology and pathway analysis uncovered the enrichment of HVEM in multiple immune regulation process, especially in the suppression of T cell mediated immunity in GBM. Moreover, HVEM was tightly associated with several infiltrating immune and stromal cell lineages in microenvironment, and showed high correlation with other immune checkpoints. CONCLUSIONS Our data highlights the importance of HVEM in GBM progression and that targeting HVEM combined with current immune checkpoint blockades might be a novel therapeutic strategy for GBM.


2017 ◽  
Vol 24 (13) ◽  
pp. 4042-4050 ◽  
Author(s):  
Julia Y. S. Tsang ◽  
Kit-Wing Chan ◽  
Yun-Bi Ni ◽  
Thazin Hlaing ◽  
Jintao Hu ◽  
...  

2019 ◽  
Vol 202 (7) ◽  
pp. 2057-2068
Author(s):  
Qinglai Meng ◽  
Asifa K. Zaidi ◽  
John Sedy ◽  
Armand Bensussan ◽  
Daniel L. Popkin

2007 ◽  
Vol 1096 (1) ◽  
pp. 89-96 ◽  
Author(s):  
M. TERESA SCIORTINO ◽  
M. ANTONIETTA MEDICI ◽  
F. MARINO-MERLO ◽  
D. ZACCARIA ◽  
M. GIUFFRE ◽  
...  

Endocrinology ◽  
2012 ◽  
Vol 153 (10) ◽  
pp. 4808-4817 ◽  
Author(s):  
Woon-Ki Kim ◽  
Ok-Joo Sul ◽  
Eun-Kyung Choi ◽  
Mi-Hyun Lee ◽  
Choon-Soo Jeong ◽  
...  

Abstract Herpes virus entry mediator (HVEM), which is constitutively expressed at a high level on myeloid lineage cells, is also expressed on bone marrow-derived macrophages, suggesting that it may play a role in bone metabolism by affecting osteoclasts (OC) derived from bone marrow-derived macrophages. To address this question, we evaluated bone mass by micro-computed tomography and the number and activity of OC by tartrate-resistant acid phosphatase (TRAP) and pit formation on dentine slices, comparing HVEM-knockout mice with wild-type mice. The absence of HVEM led to a higher bone mass and to decreased levels of serum collagen type I fragments and serum TRACP5b in vivo. In vitro HVEM deficiency resulted in a reduced number and activity of OC and an impaired receptor activator of nuclear factor-κB ligand signaling through reduced activation of nuclear factor-κB and of nuclear factor of activated T-cells cytoplasmic 1. Exogenous soluble HVEM decreased expression of TRAP, whereas soluble LIGHT (a ligand of HVEM) increased it, indicating the occurrence of a positive signaling through HVEM during osteoclastogenesis. Our findings indicate that HVEM regulates bone remodeling via action on OC. The higher bone mass in the femurs of HVEM-knockout mice could be, at least in part, due to attenuated osteoclastogenesis and bone resorption resulting from decreased receptor activator of nuclear factor-κB ligand signaling in the OC.


Sign in / Sign up

Export Citation Format

Share Document